The Board of Directors acknowledged his request during its meeting October 29, 2026. The company explains Nani decided to step down because of his wish to spend more time with his family and loved ones. Until December 4, 2026, Ioan Nani will continue to exercise his duties in full and together with the Board of Directors will oversee the transition process.
Nani joined Antibiotice as an economist in 1987, became chief financial officer in 1994 and chief executive officer in 1998. In his position as CFO, he prepared the floatation of the company on the Bucharest Stock Exchange.
During his time at the helm, according to his CV, revenue went up 38% in 2020-2022, going from RON341 million (EUR64 million) to RON472 million (EUR88 million), while exports increased from RON158 million (EUR30 million) to RON178 million (EUR33 million) and the company also inaugurated a topical product factory, following a EUR21 million investment. Antibiotice exports to 70 countries and is a world leading producer of nystatin.
For the period following December 4, 2026, the Board of Directors will appoint an interim chief executive officer and conduct the selection process for a new chief executive officer in accordance with Government Emergency Ordinance No. 109/2011 on the corporate governance of public enterprises. The General Meeting of Shareholders will also be convened to appoint an interim member of the Board of Directors and start the selection process for a new Board member for a full term.
(English version by Loredana Fratila-Cristescu)